PRCT
PROCEPT BioRobotics Corporation Healthcare - Surgical Robotics Investor Relations →
PROCEPT BioRobotics Corporation (PRCT) closed at $25.79 as of 2026-03-20, trading 45.7% below its 200-week moving average of $47.46. This places PRCT in the extreme value zone. The stock is currently moving closer to the line, down from -42.9% last week. With a 14-week RSI of 29, PRCT is in oversold territory.
Trading volume is running at 1.1x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.24 ratio) is neutral — neither side is clearly dominating.
Over the past 187 weeks of data, PRCT has crossed below its 200-week moving average 4 times. On average, these episodes lasted 17 weeks. Historically, investors who bought PRCT at the start of these episodes saw an average one-year return of +60.3%.
With a market cap of $1454 million, PRCT is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -24.9%. The stock trades at 4.0x book value.
Share count has increased 25.6% over three years, indicating dilution.
Over the past 3.7 years, a hypothetical investment of $100 in PRCT would have grown to $64, compared to $173 for the S&P 500. PRCT has returned -11.5% annualized vs 16.1% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 2 open-market purchases totaling $11,268,081. Notably, these purchases occurred while PRCT is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: PRCT vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After PRCT Crosses Below the Line?
Across 4 historical episodes, buying PRCT when it crossed below its 200-week moving average produced an average return of +71.3% after 12 months (median +65.0%), compared to +24.7% for the S&P 500 over the same periods. 100% of those episodes were profitable after one year. After 24 months, the average return was +69.0% vs +44.3% for the index.
Each line shows $100 invested at the moment PRCT crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
PRCT has crossed below its 200-week MA 4 times with an average 1-year return of +60.3% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Feb 2023 | Apr 2023 | 7 | 21.1% | +35.1% | -28.6% |
| Apr 2023 | Jul 2023 | 10 | 20.3% | +70.5% | -15.1% |
| Jul 2023 | Nov 2023 | 17 | 25.7% | +75.3% | -26.9% |
| Aug 2025 | Ongoing | 33+ | 52.3% | Ongoing | -32.9% |
| Average | 17 | — | +60.3% | — |
Frequently Asked Questions
Is PRCT below its 200-week moving average?
Yes. As of 2026-03-20, PROCEPT BioRobotics Corporation (PRCT) is trading 45.7% below its 200-week moving average of $47.46. The current price is $25.79.
What is PRCT's 200-week moving average price?
PROCEPT BioRobotics Corporation's 200-week moving average is $47.46 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when PRCT drops below its 200-week moving average?
PRCT has crossed below its 200-week moving average 4 times in our data. On average, buying at that moment produced a one-year return of +60.3%. These dips have historically been decent entry points. These episodes lasted 17 weeks on average.
Is PRCT a good value right now?
Here's what our data says about PRCT as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 29 (oversold). Free cash flow is currently negative. Return on equity is -24.9%. Price-to-book is 4.0x. This is not a buy or sell recommendation — always do your own research.
How does PRCT compare to the S&P 500?
Over the past 3.7 years, $100 invested in PRCT would have grown to $64, compared to $173 for the S&P 500. That's -11.5% annualized vs 16.1% for the index. PRCT has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20